These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15704667)

  • 1. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis.
    Matsuse D; Ochi H; Tashiro K; Nomura T; Murai H; Taniwaki T; Kira J
    Intern Med; 2005 Jan; 44(1):68-72. PubMed ID: 15704667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsing demyelinating disease affecting both the central and peripheral nervous systems.
    Zéphir H; Stojkovic T; Latour P; Lacour A; de Seze J; Outteryck O; Maurage CA; Monpeurt C; Chatelet P; Ovelacq E; Vermersch P
    J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1032-9. PubMed ID: 18208860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic inflammatory demyelinating polyradiculoneuropathy associated with multiple sclerosis.
    Sharma KR; Saadia D; Facca AG; Bhatia R; Ayyar DR; Sheremata W
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):385-96. PubMed ID: 18525422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum.
    Shimizu J; Hatanaka Y; Hasegawa M; Iwata A; Sugimoto I; Date H; Goto J; Shimizu T; Takatsu M; Sakurai Y; Nakase H; Uesaka Y; Hashida H; Hashimoto K; Komiya T; Tsuji S
    Neurology; 2010 Oct; 75(16):1423-7. PubMed ID: 20826711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination.
    Pirko I; Kuntz NL; Patterson M; Keegan BM; Weinshenker BG; Rodriguez M
    Neurology; 2003 May; 60(10):1697-9. PubMed ID: 12771272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History of modern multiple sclerosis therapy.
    Lublin F
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
    Jeffery DR; Chepuri N; Durden D; Burdette J
    Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
    Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
    J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
    Grimm A; Vittore D; Schubert V; Rasenack M; Décard BF; Heiling B; Hammer N; Axer H
    J Neurol; 2016 Jun; 263(6):1074-82. PubMed ID: 27017343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b.
    Markovic-Plese S; Bielekova B; Kadom N; Leist TP; Martin R; Frank JA; McFarland HF
    Neurology; 2003 Jun; 60(11):1849-51. PubMed ID: 12796549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrodiagnostic criteria in CIDP: comparison with diabetic neuropathy.
    Wilson JR; Park Y; Fisher MA
    Electromyogr Clin Neurophysiol; 2000; 40(3):181-5. PubMed ID: 10812541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain as the presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
    Boukhris S; Magy L; Khalil M; Sindou P; Vallat JM
    J Neurol Sci; 2007 Mar; 254(1-2):33-8. PubMed ID: 17286985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1a as an investigational treatment for CIDP.
    Vallat JM; Hahn AF; Léger JM; Cros DP; Magy L; Tabaraud F; Bouche P; Preux PM
    Neurology; 2003 Apr; 60(8 Suppl 3):S23-8. PubMed ID: 12707419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
    Goodin DS; Reder AT; Ebers GC; Cutter G; Kremenchutzky M; Oger J; Langdon D; Rametta M; Beckmann K; DeSimone TM; Knappertz V
    Neurology; 2012 Apr; 78(17):1315-22. PubMed ID: 22496198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis.
    Khan OA; Hebel JR
    Ann Neurol; 1998 Jul; 44(1):138-9. PubMed ID: 9667604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
    Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
    Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.